Promoter holding
64.27%
LP
Lok-Beta Pharmaceuticals (India )Private Limited - Due diligence report
A 360° intelligence report on Lok-Beta Pharmaceuticals (India )Private Limited: trust score, financial health, credit view, compliance, dire…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Lok-Beta Pharmaceuticals (India )Private Limited — 360° Intelligence Report
Generated from MCA filings & public records92/100
Trust Score
Low Risk
Lok-Beta Pharmaceuticals (India )Private Limited is assessed as Low Risk with a Trust Score of 92/100. Lok-Beta Pharmaceuticals (India )Private Limited is an active private limited indian non-government company incorporated in 2002, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 11 Aug 2026 from the latest processed filings. Lok-Beta Pharmaceuticals (India )Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 50/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 1.42).
- Profitable - internal accruals available.
Charges position: 7 open (37.30 cr) · 1 satisfied (9.31 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Axis Bank Limited | 6 | 48.0 cr |
| State Bank Of India | 2 | 48.0 cr |
Compliance Score: 88/100 Low Risk
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- 2 active GST registration(s).
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SUDHANSHU KUMAR SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| HINA KIRAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ALOK AWADHESH KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ASHISH KUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2021 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
2 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Novalok Llc, Belarus | Subsidiary Company | 74.00% |
| J Duncan Healthcare Private Limited | Associate Company | 74.00% |
Key managerial personnel: ALOK AWADHESH KUMAR (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Operating for 24+ years.
Active GST registration(s).
Distress signals & risk flags
7 open charge(s) registered - assets are encumbered.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence90/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment73/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 7 open charge(s) of 37.30 cr already registered.
- Compliance record supports lending.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
01 Dec 2022
Director appointed
ASHISH KUMAR (Director)
25 May 2022
Charge created
Axis Bank Limited - 2.24 cr
22 Apr 2022
Charge created
Axis Bank Limited - 2.15 cr
01 Apr 2022
Director ceased
HINA KIRAN
26 Mar 2021
Charge created
State Bank Of India - 2.40 cr
17 Feb 2021
Charge created
Axis Bank Limited - 10.00 cr
08 Jan 2021
Charge created
Axis Bank Limited - 1.24 cr
29 Oct 2020
Charge created
Axis Bank Limited - 3.27 cr
12 Aug 2020
Director ceased
RINA SINGH
29 Aug 2017
Charge created
Axis Bank Limited - 16.00 cr
30 Mar 2017
Securities allotted
4890 Equity Shares Without Differential Rights - 40.00 Lakh raised
Director ceased
SATYAKAM KIRAN KASHYAP
01 Mar 2017
Director ceased
SHAKUNTALA AWADHESHKUMAR SINHA
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
4 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2021 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
59 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Ridhi Petrochem Private Limited | U24100GJ2005PTC145668 | Ahmadabad City, Gujarat, India |
| Vovantis Laboratories Private Limited | U24230GJ2008PTC055176 | Vadodara, Gujarat, India |
| Tagoor Chemicals Private Limited | U24233TG2009PTC062705 | Hyderabad, Telangana, India |
| Cipy | U24219PN1994PTC083328 | Pune, Maharashtra, India |
| Kerala State Industrial Enterprises Ltd | U63013KL1973SGC002477 | Thiruvananthapuram, Kerala, India |
| Angelspharma | U24233TG2016PTC103989 | Hyderabad, Telangana, India |
| Aurochem Laboratories (India) Private Limited | U24230MH1997PTC112098 | Mumbai, Maharashtra, India |
| Piramal | U24100MH2014PTC373507 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Lok-Beta Pharmaceuticals (India )Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Lok-Beta Pharmaceuticals (India )Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Lok-Beta Pharmaceuticals (India )Private Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Lok-Beta Pharmaceuticals (India )Private Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Lok-Beta Pharmaceuticals (India )Private Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Lok-Beta Pharmaceuticals (India )Private Limited an active company?
Lok-Beta Pharmaceuticals (India )Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).
Is Lok-Beta Pharmaceuticals (India )Private Limited financially healthy?
Lok-Beta Pharmaceuticals (India )Private Limited has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Lok-Beta Pharmaceuticals (India )Private Limited?
Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Lok-Beta Pharmaceuticals (India )Private Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.
Does Lok-Beta Pharmaceuticals (India )Private Limited have loans or charges against its assets?
7 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Lok-Beta Pharmaceuticals (India )Private Limited up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).
Is it risky to lend to Lok-Beta Pharmaceuticals (India )Private Limited?
Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
